No Data
No Data
Tibet Pharmaceutical (600211.SH): The product does not cover the category of synthetic organisms
Gelonghui, May 10 丨 Tibet Pharmaceutical (600211.SH) said on the investor interactive platform that the company's products do not yet cover the category of synthetic organisms.
Tibet Pharmaceutical (600211.SH) announced first-quarter results, net profit of 313 million yuan, up 3.21% year on year
Tibet Pharmaceutical (600211.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 7.0 during the reporting period...
Tibet Pharmaceutical (600211.SH) plans to distribute 0.737 yuan per share to increase 0.3 shares in 2023, excluding interest on April 30
Tibet Pharmaceutical (600211.SH) announced that the company plans to distribute a cash dividend of 0.737 per share in 2023...
Tibet Pharmaceutical (600211.SH): Since Neoactive entered the medical insurance list in 2017, sales have risen sharply in recent years
Gelonghui, April 10 | Tibet Pharmaceutical (600211.SH) said at the performance briefing that sales of Neoactive have risen sharply in recent years since entering the medical insurance catalogue in 2017. According to the company's 2024 performance guidelines, sales of Neoactive are expected to maintain a continuous growth trend. The company will make every effort to do a good job in product sales and promote the steady growth of business performance.
Tibet Pharmaceutical (600211.SH): Received 86.2 million yuan in industrial support funds
Gelonghui, March 29丨Tibet Pharmaceutical (600211.SH) announced that the company and its subsidiary, Tibet Nordicom Pharmaceutical Co., Ltd. received 86,202,742 yuan in industrial development support funds from the Shannan Happy Home Construction Administration on March 29, 2024, accounting for 10.76% of the company's most recent (2023) audited net profit attributable to shareholders of listed companies.
Tibet Pharmaceutical (600211.SH) reported 2023 results, net profit of 801 million yuan, an increase of 116.56% year-on-year
According to the Zhitong Finance App, Tibet Pharmaceutical (600211.SH) released its 2023 annual report, achieving operating revenue of 3.134 billion yuan, an increase of 22.69% over the previous year. Achieved net profit of 801 million yuan attributable to shareholders of listed companies, an increase of 116.56% over the previous year. Achieved net profit of 784 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 112.49% over the previous year. Cash of 7.37 yuan (tax included) is distributed to all shareholders for every 10 shares, while 3 shares are added for every 10 shares using the capital reserve fund. During the reporting period, operating income increased by 22.69%, returning net profit to mother
No Data